[
  {
    "ts": null,
    "headline": "Viatris (VTRS): Assessing Valuation After New AI-Powered Bacteriophage Partnership with Locus Biosciences",
    "summary": "Viatris (VTRS) just announced a strategic partnership with Locus Biosciences to develop new bacteriophage therapies for drug-resistant eye infections. The collaboration brings together cutting-edge AI and synthetic biology, providing new alternatives to traditional antibiotics. See our latest analysis for Viatris. Viatris’s recently announced partnership to tackle drug-resistant infections is catching attention at a time when its stock is trying to regain momentum. After some challenging...",
    "url": "https://finnhub.io/api/news?id=97858d88a2c536c3babae395d1e36e3b4070f744723c60f63cb9924327fe0ddf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761890884,
      "headline": "Viatris (VTRS): Assessing Valuation After New AI-Powered Bacteriophage Partnership with Locus Biosciences",
      "id": 137275484,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VTRS",
      "source": "Yahoo",
      "summary": "Viatris (VTRS) just announced a strategic partnership with Locus Biosciences to develop new bacteriophage therapies for drug-resistant eye infections. The collaboration brings together cutting-edge AI and synthetic biology, providing new alternatives to traditional antibiotics. See our latest analysis for Viatris. Viatris’s recently announced partnership to tackle drug-resistant infections is catching attention at a time when its stock is trying to regain momentum. After some challenging...",
      "url": "https://finnhub.io/api/news?id=97858d88a2c536c3babae395d1e36e3b4070f744723c60f63cb9924327fe0ddf"
    }
  }
]